Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.

@article{Kraiem2012FrequencyOS,
  title={Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.},
  author={I. Kraiem and S. Hadhri and H. el Omri and R. Sassi and W. Chaabani and S. Ennabli and H. Skouri},
  journal={Annales de biologie clinique},
  year={2012},
  volume={70 6},
  pages={
          659-65
        }
}
  • I. Kraiem, S. Hadhri, +4 authors H. Skouri
  • Published 2012
  • Medicine
  • Annales de biologie clinique
  • Production of factor VIII or factor IX inhibitors is a major complication limiting the efficiency of substitutive therapy in haemophiliacs. Moreover, viral infections, the second serious complication of replacement therapy, may be associated to the occurrence of antiphospholipid antibodies which paradoxically lead to thrombosis. We investigated the prevalence of coagulation inhibitors (factor VIII and factor IX inhibitors, antiphospholipid antibodies) in Tunisian haemophiliacs, and we assessed… CONTINUE READING
    2 Citations

    References

    SHOWING 1-10 OF 39 REFERENCES
    Factor VIII haplotypes frequencies in Tunisian hemophiliacs A
    • 7